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Abstract
Congenital hypothyroidism is one of the commonest preventable causes of mental 
retardation is also the most common congenital endocrine disorder of childhood. The 
subtlety of clinical features and protective effect of the maternal hormone on fetal brain 
after crossing the placenta mask the clinical features. The incidence varies from 1 in 
4000 to 1 in 1000 in newborn infants in various parts of world and is increasing world­
wide. Thyroid agenesis remains the most common etiology of CH and other causes 
are dyshormonogenesis, defects in peripheral thyroid hormone transport, metabolism, 
or action. CH is usually diagnosed after neonatal screening tests and if treatment 
started with in few weeks of birth neurodevelopmental outcome is usually normal. 
Levothyroxine (T4) remains the treatment of choice as most brain T3 is derived from 
local monodeiodination of T4 and studies have shown normal serum level of T3 in 
infant treated with T4 alone.
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1. Introduction
Congenital hypothyroidism (CH), one of the commonest preventable causes of mental retar 
dation is also the most common congenital endocrine disorder of childhood [1]. Neuro­
developmental outcome is usually better if treatment is started within in few weeks of birth 
[2]. The subtlety of clinical features and the maternal hormone crossing the placenta provides 
a protective effect on the fetal brain masking the clinical signs [3]. In addition to this even the 
most severe forms of CH have some functioning residual thyroid tissue further making clini­
cal diagnosis difficult [4]. As the age of the neonate progresses so does the hypothyroxinemia 
leading to progression of the clinical signs and symptoms which increases the risk for irre­
versible brain injury. To prevent this, treatment needs to be started as soon as possible after 
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birth. For all the above reasons, screening has evolved as the best way to detect infants with 
CH in developed countries. In North America, more than 1400 infants out of the 5 million 
newborns screened are diagnosed with CH annually.
2. Epidemiology
The incidence of CH varies from 1 in 4000 to 1 in 1000 in newborn infants as has been reported 
from various parts of world [5]. Developing countries like India and Iran have a higher inci­
dence of CH [6, 7]. In countries like The US, Canada, New Zealand, Italy, Greece and Argentina 
the incidence of CH has nearly doubled since the introduction of newborn screening pro­
grammes [5, 8–12]. Widespread lowering of screening cutoffs in newborn screening programs 
[5, 8], increase detection of milder cases of CH, increase screening of higher risk newborn 
preterm and low birth infants, increased number of birth among Hispanic and of low birth 
weight [13] are some of the supposed causes that have been proposed as a possible cause for 
the increase in the incidence of CH. The incidence of CH is higher among Hispanic and Asian 
individuals and lower in black individuals [10, 13]. There has been a dramatic increase in the 
incidence of congenital hypothyroidism detected by the newborn screening programs, the 
incidence has risen from 1:3985 (in 1987) to 1:2273 (in 2002) [14]. This dramatic increase may 
be attributed to a spurt in the Asian (37%) and Hispanic (53%) births over the same period [13].
3. Etiology
Abnormal development of thyroid gland (thyroid dysgenesis) is the most common cause of 
CH. Thyroid dysgenesis accounts for 85% of cases of CH and is usually sporadic. It has three 
major forms thyroid ectopy, athyreosis and thyroid hypoplasia. Thyroid ectopy: it is the most 
common form and accounts for two thirds of cases of thyroid dysgenesis and is twice more 
common in females [15]. The exact etiology of thyroid dysgenesis is not known but largely 
its considered a sporadic disease and although the etiology remains elusive in most of cases 
some mutations in transcription factor genes i.e. TSHR, PAX8, NKX2­1, FOXE1, that regulate 
thyroid gland development have been reported, but only 2–5% of cases with thyroid dysgen­
esis are found to have such genetic mutations [16]. Recently, several other genes have found 
to be associated with thyroid gland dysgenesis, including NKX2­5, JAG1 and GLIS3 although 
each of them contributes to only a small fraction of cases [17–21]. Each of these transcription 
factors has a role in the development of organ systems too, and mutations of these genes 
are generally associated with additional congenital defects. In remaining one­third of cases, 
CH results from absence of thyroid (athyrosis) and thyroid hypoplasia. Dyshormonogenesis, 
or defects in peripheral thyroid hormone transport, metabolism, or action are accounted in 
approximately 15% of cases [22]. Defects in thyroid hormone biosynthesis are familial and 
usually autosomal recessive in inheritance [23]. These include mutations in the genes coding 
for the sodium­iodide symporter (NIS; SLC5A5), thyroid peroxidase (TPO), thyroglobulin 
(Tg), apical iodide transporter pendrin (PDS; SLC26A4), iodotyrosine deiodinase (IYD), 
dual oxidase (DUOX2) and its necessary protein(DUOXA2) [23]. Defective thyroid hormone 
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transport (mutations in monocarboxylase transporter 8), metabolism (selenocysteine insertion 
sequence­binding protein 2), or resistance to action (mutations of thyroid hormone receptor) 
are some rare causes. Among the aforementioned defects, mutations of the thyroid peroxi­
dase (TPO) gene form the most prevalent cause of inherited defects in CH [24]. The incidence 
of thyroid dyshormonogenesis has been increasing and now accounts for 30–40% case of CH 
but thyroid dysgenesis remains the most common cause of CH [12].
Maternal thyrotropin receptor–blocking antibodies, exposure to maternal antithyroid medi­
cations, iodine deficiency or iodine excess are the major causes of transient CH in children.
Central congenital hypothyroidism is rare and is usually associated with and is usually associ­
ated with developmental anomaly of the pituitary gland and is usually associated with other 
pituitary hormone deficiencies like adrenocorticotropin and gonadotropins [25]. If isolated, 
it usually results from a mutation in the thyroid stimulating hormone β TSHβ subunit gene 
or TRH receptor gene. Less often it is due to mutation in transcription factor gene regulating 
pituitary development i.e. HESX1, LHX3, LHX4, OTX2, SOX3, PIT1 and PROP1 [1].
4. Diagnostic evaluation
In countries with newborn screening programs CH is diagnosed after neonatal screening 
tests. However, only 25% of the world wide birth population has the access and undergoes the 
said screening tests [26]. For the remaining 75% infants, particularly concentrated in develop­
ing countries, clinical suspicion of hypothyroid leads to thyroid function evaluation.
4.1. Newborn thyroid screening protocols
48–72 h after birth is the ideal time for the newborn screening tests, the reason being that the 
physiological surge in TSH that occurs after the first hours after birth to a peak serum level of 
80 mIU/L slowly starts to decrease over the next several days [27]. Sample taken within 48 h 
of birth may lead to false positive results whereas screening done in very sick newborn or 
following blood transfusion may lead to false negative result.
In case of a critically ill new born, preterm birth or in case of a home delivery sample should 
be collected by 7 days of age. Capillary blood samples taken by heel prick method are placed 
on circles of specialize filter paper, dried at room temperature, then sent to a centralized 
laboratory. Second blood sample taken at 2–4 week is a part of the protocol in some screening 
programs. The additional incidence of CH based on a second screening at 2 weeks of age 
is approximately 1 in 30,000 [28, 29]. Preterm and LBW infants, critically ill infants, same­
sex twins, and infants whose initial screen was performed in the first 24 h of life are some 
examples where a routine second screening must be performed [30].
Earlier the screening protocol for CH was T4 estimation followed by TSH only if t4 was low 
however with increasing accuracy of TSH assays on small volumes of blood, initial TSH test­
ing has become the sine qua non of most screening protocols [31]. Both methods allow for the 
detection of most of the infants having CH but each method has its own merits and demer­
its. Measuring T4 first and then TSH detects some cases of secondary hypothyroidism and 
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infants that might have “delayed TSH elevation” whereas measuring TSH first and then T4 
also detects mild or subclinical forms of hypothyroidism. Broadly speaking, if the screening 
T4 value is less than 10th percentile of cut off and/or the TSH is greater than 40 mU/L, the 
infant should be called again for confirmatory serum testing. In cases having “intermediate 
results,” TSH 20–40 mU/L, recommendation is to repeat TSH screening in early second week 
of life. A TSH value <20 mIU/L is considered as normal.
4.2. Confirmatory serum thyroid testing
Diagnosis must not be completely and solely reliant on the screening tests only they must be 
confirmed by serum testing, venipuncture blood should be drawn and serum should be sent for 
TSH and free T4, or total T4 and T3 resin uptake as some measure of binding proteins. These 
serum based results must be compared with age normalized values as during the first week of 
life TSH and T4 are fluctuant [32]. Most confirmatory serum tests could be obtained in first 2 
weeks of life, as during this upper TSH range has fallen to an around 10 mU/L. Although all hor­
mones are higher during first week of age they come down to infancy range within 2–4 weeks.
5. Test results
5.1. Low T4 and elevated TSH values
A low total serum T4 or free T4 level along with an elevated serum TSH level confirms the 
diagnosis of primary hypothyroidism and levothyroxine (L­T4) must be started immedi­
ately after the confirmatory tests are done even before the results are available. Before age 
of 2 weeks, venous TSH >20 mIU/L and after 2 weeks, TSH > 10 mIU/L, suggests primary 
CH [33]. Serum T4 < 10 μg/dL (<128 nmol/L) or FT4 < 1.17 ng/dL (<15 pmol/L) is considered 
low in infancy.
5.2. Normal T4 and elevated TSH values
A transient or permanent thyroid dysfunction or delayed maturation of the hypothalamic–pitu­
itary axis is indicated by normal levels of total T4 or free T4 along with elevated TSH. Initiating 
levothyroxine in such cases is still controversial. Since TSH concentration is the most sensitive 
indicator of hypothalamic-pituitary-thyroid axis therefore when confirmatory serum TSH level 
is between 6 and 20 mIU/L with normal FT4 levels, it is reasonable to watch serum thyroid func­
tion tests closely (every 1–2 weeks) and not start LT4 and if TSH is increases or if FT4 decreases 
to below normal level, treatment should be initiated. After 2 weeks of age a TSH > 10 mU/L is 
considered abnormal [34, 35]. And if TSH elevation persists, the infant must be treated.
5.3. Low T4 and normal TSH values
Hypothalamic immaturity particularly in preterm infants, in infants during illness, in cen­
tral hypothyroidism or in primary hypothyroidism and delayed TSH elevation low T4 with 
normal TSH may be seen. No guidelines exists for the follow­up of these patients, but they 
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can be followed with serial filter-paper screening tests until the T4 value becomes normal, 
or a second blood sample for measurement of serum FT4 and TSH can be obtained. Such 
infants are usually found to have normal thyroid profile on subsequent screening tests. Their 
treatment (except those with central hypothyroidism) with L­T4 has not yet been shown to 
be beneficial [36].
6. Diagnostic studies to determine an underlying etiology
Since additional investigations for etiology do not alter the treatment plan they can be delayed. 
Treatment of CH should never be deferred after confirmation pending the determination of 
etiology.
6.1. Thyroid radionuclide uptake and scan
Thyroid radionuclide uptake and scanning is the most accurate imaging modality to deter­
mine the size and location of thyroid tissue. Iodine­123 (I­123) or sodium pertechnetate 99 m 
(Tc99m) are tracers of choice as I­131 delivers a higher dose of radioactivity. Radionuclide 
uptake and scan is used to identify thyroid aplasia (absent uptake), hypoplasia (decreased 
uptake, small gland in a eutopic location) or an ectopic gland. Other conditions not showing 
any uptake include; TSHβ gene mutations, TSH receptor inactivating mutations, iodide trap­
ping defects and in those with maternal thyrotropin receptor blocking antibodies (TRB­Ab). 
Dyshormonogenesis beyond trapping of iodide results in a large gland in a eutopic location 
with increased uptake on the scan. A perchlorate discharge test can be performed to confirm 
the diagnosis of dyshormonogenic CH.
6.2. Thyroid ultrasound
When it comes to etiology determination thyroid ultrasound is usually the first modality per­
formed. It confirms thyroid aplasia when radionuclide scan show absent uptake. TSHβ gene 
mutations, TSH receptor inactivating, iodide trapping defect and maternal TRB­Ab shows 
the absence of radionuclide uptake in the presence of thyroid gland in the normal position. 
Dyshormonogenesis is associated with absent uptake in radionuclide scan and large thyroid in 
ultrasound. Color Doppler flow may be able to detect up to 90% of cases of ectopic thyroid [37].
6.3. Serum thyroglobulin (Tg) measurement
Serum thyroglobulin is reflective of the thyroid mass and is usually raised in increased activ­
ity of the thyroid gland. In a recent study, Beltrão et al., suggested that color Doppler ultra­
sound combined with serum thyroglobulin measurement may become very valuable tools 
for the diagnosis of the cause of CH and will also help minimize more harmful tests, like 
radionuclide scan [38]. Increased thyroglobulin levels and absent uptake on radionuclide scan 
suggests presence of thyroid gland along with a TSH receptor inactivating mutation, a trap­
ping defect, or maternal TRB­Ab, rather than aplasia.
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6.4. Thyroid receptor antibody
Transient CH in children can also be caused by maternal thyroid receptor blocking antibodies 
TRB­Ab. Absent radionuclide uptake with small or normal sized eutopic gland suggests tran­
sient congenital hypothyroidism as a result of transplacental passage of the antibody from the 
mother to the child. For confirmation the measurement of serum TRB-Ab in mother and/or 
infant may be done by a thyrotropin­binding inhibitor immunoglobulin (TBII) assay.
6.5. Urinary iodine estimation
24 h urinary iodine excretion approximates the iodine ingestion. For neonates the normal 
range is approximately 50–100 mg/24 h. Urinary iodine measurement may provide confirma­
tion regarding iodine deficiency or excess.
7. Management
CH remains the most common preventable cause of mental retardation. Studies have shown 
that timing and dosing of thyroid hormone replacement are both crucial for neurological 
outcome. The infant must be rendered euthyroid as early as possible by starting the treatment 
promptly and at sufficient dose, as there is an inverse relationship between intelligence quo­
tient (IQ) and the age of diagnosis. Despite early diagnosis the neurological outcome may be 
poor due to delay in starting treatment, lower starting thyroid hormone dosing and severity 
of the hypothyroidism, which itself correlates with the underlying etiology [39].
7.1. Formulation
Levothyroxine (l­thyroxine) remain the treatment of choice. Although biologically active 
form is triiodothyronine (T3) but most brain T3 is derived from local monodeiodination of T4. 
As studies have shown normal serum level of T3 in infant treated with T4 alone, so treatment 
with T3 is not essential for normal neurological outcome/brain development [40]. Currently, 
only tablets form of l­thyroxine are approved for use owing to inconsistent delivery of liquid 
formulations. However, in some countries in Europe, l­thyroxine suspension is also available 
and is used to normalize thyroid function.
7.2. Administration
Crushed levothyroxine (l­thyroxine) tablet is mixed with 1–2 ml of breast milk, formula or 
water and resultant suspension is squirted into cheek pad or put on open nipple for infant to 
feed. Various substances like such as calcium and iron preparation, soy protein formula, sucral­
fate, aluminum hydroxide and cholestyramine interfere levothyroxine (l­thyroxine) absorp­
tion through gut and thus should not be given together [41, 42]. Although, recommendation is 
to take levothyroxine (l­thyroxine) empty stomach but for infant it may not be feasible.
Thyroid Disorders10
7.3. Dosages
For the optimal neurodevelopmental outcome, the treatment goal is to normalize T4 and TSH 
within 2 and 4 weeks respectively [33, 43, 44]. In a study infants had significant lower cognitive, 
attention and achievement scores who took more than 2 weeks to normalize thyroid function 
compared to infants who attained normal thyroid function at 1 or 2 weeks of treatment [45]. 
Adequacy and the timing of treatment determines optimal neurodevelopmental outcome and 
thus American academy of pediatrics and European society of pediatric endocrinology rec­
ommend 10–15 μgm/kg/day as initial dose [46]. Studies show that this dose normalizes serum 
T4 within 3 days and TSH within 2–4 weeks. To achieve these goals, it is important to start 
higher initial dose of the recommended range in case of severe CH. In a study infants who 
were started on higher initial doses of 50 μgm had full­scale IQ scores 11 points higher than 
those started on lower initial doses of 37.5 μgm [45].
7.4. Target concentrations
The target T4 concentrations lies in the upper half of reference range according to the 
Guidelines issued by the American academy of pediatrics and European society for pediatric 
endocrinology [30, 47–49]. Target values for T4 being 10–16 μgm/dl; FT4 1.4–2.3 ng/dl and 
TSH <5 μU/dl (optimally 0.5–2.0 μU/dl) for initial 3 years of life following this T4 should be 
kept in the upper half of normal range. Low IQ in infants with T4 concentration below 10 
μgm/dl and TSH above 15 μU/dl was seen during the first year of life compared to those had 
serum T4 more than 10 μgm/dl [50]. Better intellectual outcome in children with CH was seen 
with higher doses of levothyroxine (l­thyroxine) [51]. Contrary to this other studies have 
shown behavior problems like increased anxiety, social withdrawal and poor concentration 
with higher doses in children at age of 8 years. Thus demonstrating potential dangers of 
overtreatment with levothyroxine in CH children [52].
8. Follow-up
Congenital anomalies are also more frequent in CH than in general population (10% in CH com­
pared to 3% in general population) most common of these anomalies is cardiac malformation 
particularly pulmonary stenosis, atrial septal defect and ventricular septal defect. Adequate 
monitoring is required to maintain the thyroid functions within the recommended levels. The 
American Academy of Pediatrics recommends the following monitoring schedule [53].
• At 2 and 4 weeks after the initiation of l­thyroxine treatment.
• Every 1–2 m during the first 6 m of life.
• Every 3–4 m between 6 m and 3 years of age
• Every 6–12 m thereafter until growth is complete
Congenital Hypothyroidism
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• Four weeks after any change in dose or more frequently if results are abnormal or non­
compliance is suspected.
To ensure adequate growth and neurological development of the infant clinical evaluation 
should be carried out even more frequently than lab investigation.
8.1. Unresolved controversy
The incidence of congenital hypothyroidism is seemingly on the rise. Whether this increase is 
absolute or the result of lowering of screening test cutoff or changes in the racial and demo­
graphic profile or something else remains to be determined. This rise may also be the result 
of a larger reach of the screening test or the detection of infants with mild hypothyroidism 
and those with “delayed TSH rise”. As already mentioned the most common cause of CH is 
thyroid dysgenesis, but the underlying etiology of thyroid dysgenesis remains an enigma. 
Only 2% cases of thyroid dysgenesis caused by genetic mutation in genes that encode for thy­
roid transcription factors. The other issue at hand is whether the rise of TSH is permanent or 
temporary we require more studies in affected infants detected by abnormalities on a second 
screening test to resolve this controversy.
9. Conclusion
Congenital hypothyroidism (CH) is one of the most common preventable cause of mental 
retardation. Screening of large populations of newborns is best method to diagnose infants 
with CH. If the diagnosis is made and treatment started within a few weeks of birth, neuro­
developmental outcome generally is normal. The underlying etiology of the most common 
cause of CH, thyroid dysgenesis, is largely unknown.
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